BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Raschi E, De Ponti F. Strategies for Early Prediction and Timely Recognition of Drug-Induced Liver Injury: The Case of Cyclin-Dependent Kinase 4/6 Inhibitors. Front Pharmacol 2019;10:1235. [PMID: 31708776 DOI: 10.3389/fphar.2019.01235] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Steger-hartmann T, Raschke M. Translating in vitro to in vivo and animal to human. Current Opinion in Toxicology 2020;23-24:6-10. [DOI: 10.1016/j.cotox.2020.02.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Mozzanega B. Ulipristal acetate and liver-injuries: while Esmya is revoked, EllaOne is allowed in repeated self-administrations possibly exceeding UPA toxic-dosing with Esmya. Journal of Hepatology 2021;74:750-1. [DOI: 10.1016/j.jhep.2020.11.041] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
3 Finnsdottir S, Sverrisdottir A, Björnsson ES. Hepatotoxicity associated with ribociclib among breast cancer patients. Acta Oncol 2021;60:195-8. [PMID: 33272079 DOI: 10.1080/0284186X.2020.1853228] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Dinis-Oliveira RJ. Pharmacokinetics, toxicological and clinical aspects of ulipristal acetate: insights into the mechanisms implicated in the hepatic toxicity. Drug Metab Rev 2021;:1-9. [PMID: 33905271 DOI: 10.1080/03602532.2021.1917599] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Zahmatkesh E, Ghanian MH, Zarkesh I, Farzaneh Z, Halvaei M, Heydari Z, Moeinvaziri F, Othman A, Ruoß M, Piryaei A, Gramignoli R, Yakhkeshi S, Nüssler A, Najimi M, Baharvand H, Vosough M. Tissue-Specific Microparticles Improve Organoid Microenvironment for Efficient Maturation of Pluripotent Stem-Cell-Derived Hepatocytes. Cells 2021;10:1274. [PMID: 34063948 DOI: 10.3390/cells10061274] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Xiao RR, Lv T, Tu X, Li P, Wang T, Dong H, Tu P, Ai X. An integrated biomimetic array chip for establishment of collagen-based 3D primary human hepatocyte model for prediction of clinical drug-induced liver injury. Biotechnol Bioeng 2021;118:4687-98. [PMID: 34478150 DOI: 10.1002/bit.27931] [Reference Citation Analysis]
7 Beachler DC, de Luise C, Jamal-Allial A, Yin R, Taylor DH, Suzuki A, Lewis JH, Freston JW, Lanes S. Real-world safety of palbociclib in breast cancer patients in the United States: a new user cohort study. BMC Cancer 2021;21:97. [PMID: 33494720 DOI: 10.1186/s12885-021-07790-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Jiang H, Jin Y, Yan H, Xu Z, Yang B, He Q, Luo P. Hepatotoxicity of FDA-approved small molecule kinase inhibitors. Expert Opin Drug Saf 2021;20:335-48. [PMID: 33356646 DOI: 10.1080/14740338.2021.1867104] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Nunes DRDCMA, Monteiro CSDJ, dos Santos JL. Herb-Induced Liver Injury—A Challenging Diagnosis. Healthcare 2022;10:278. [DOI: 10.3390/healthcare10020278] [Reference Citation Analysis]
10 Raschi E, Caraceni P, Poluzzi E, De Ponti F. Baricitinib, JAK inhibitors and liver injury: a cause for concern in COVID-19? Expert Opin Drug Saf 2020;19:1367-9. [PMID: 32840116 DOI: 10.1080/14740338.2020.1812191] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]